NOK 1.33
-0.00 (-0.37%)
NOK · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where HBC.OL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
11 interventional · 1 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| ProGo Menopause Wellbeing StudyNCT07611305Change in body mass index (BMI)Randomized · Triple-masked · Prevention | Not applicable | Not yet recruiting | Dietary supplement: Salmon protein hydrolysate (SPH) powder formulated into a tablet format, Microcrystalline Cellulose | Menopause Related Conditions | 100 | Dec 2026 | ≤ 133 d | 2026-06-02 |
| NT-II™ Collagen for Joint Discomfort and FunctionNCT07119645Change in participant-nominated activity-related knee discomfort (VASNA for pain) from baseline to week 12Randomized · Open-label · Treatment | Not applicable | Recruiting | Dietary supplement: NT-II™ (240 mg), NT-II™ 480 mg, Glucosamine/Chondroitin | Activity-Related Knee Discomfort, Joint Discomfort, Functional Joint Pain, Functional Knee Pain, Knee Acute and Chronic Pain | 120 | 2026-07-15 | — | 2026-05-14 |
| Unrefined Salmon Oil as Dietary Supplement in Patient With Chronic Obstructive Pulmonary DiseaseNCT05130294Level of oxidative low-density lipoprotein (ox-LDL)Randomized · Triple-masked · Prevention | Not applicable | Withdrawnsponsor's stated reason: The study was terminated before recruitment began due to administrative decision. | Dietary supplement: CARDIO®, Placebo | Chronic Obstructive Pulmonary Disease | 0 | Nov 2026 | ≤ 102 d | 2025-09-26 |
| Change in Omega 3 Index in Healthy Adults With OmeGo or a Standard Omega-3 Oil SupplementNCT06802068To assess and compare the bioavailability of a natural salmon oil with that of a standard omega-3 supplementRandomized · Open-label · Prevention | Not applicable | Completed | Dietary supplement: whole salmon oil, Cod liver oil | Supplementation in Healthy Adults to Assess Impact on Omega 3 Index and Cardiometabolic Health | 96 | 2025-12-23actual | — | 2026-02-23 |
| A Clinical Trial Investigating the Effect of Salmon Bone Meal on Bone Mass Among Osteopenic WomenNCT05066477Mean change in Bone Mass Density (BMD) of the femoral neck at Month 12, and Month 24.Randomized · Triple-masked · Prevention | Not applicable | Completed | Dietary supplement: CalGo · Other: Placebo | Osteopenia, Osteopenia of the Elderly | 80 | 2025-06-12actual | — | 2025-09-23 |
| Unrefined Salmon Oil as Dietary Supplement in Adult AsthmaticsNCT05137132Change of severe and moderate eventsRandomized · Triple-masked · Prevention | Not applicable | Completed | Dietary supplement: CARDIO®, Placebo | Asthma | 70 | 2024-12-09actual | — | 2025-09-26 |
| Investigating the Effect of Daily CARDIO® Capsules Supplementation on Improved Sleep in Healthy, Urban-Dwelling AdultsNCT06768970The impact of OmeGo capsules on sleep quantity and qualityRandomized · Open-label · Treatment | Not applicable | Completed | Dietary supplement: CARDIO® salmon oil | Sleep, Pollution; Exposure, Cough | 131 | 2024-11-15actual | — | 2025-01-10 |
| A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and WomenNCT05070871Mean change from Baseline in WOMAC composite score at Month 3 and Month 6.Randomized · Triple-masked · Prevention | Not applicable | Completed | Dietary supplement: Hydrolyzed Collagen, CalGo · Other: Placebo | Osteoarthritis, Osteoarthritis, Knee, Osteoarthritis, Hip | 98 | 2023-12-27actual | — | 2024-02-13 |
| Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19NCT04465513Proportion of patients requiring mechanical ventilator until end of study (Day 28)Randomized · Open-label · Treatment | Not applicable | Completed | Dietary supplement: Best Standard of Care + CARDIO, Best Standard of Care | COVID, Covid-19 | 14 | 2021-10-04actual | — | 2021-10-05 |
| The Impact of Salmon Protein Hydrolysate (SPH / ProGo®) Supplementation on Hematologic and Metabolic HealthNCT07616752Change in hemoglobin (g/L)Randomized · Triple-masked · Prevention | Not applicable | Completed | Other: Nutritional supplementation, Nutritional Supplement | Overweight (BMI > 25), Weight Loss | 14 | 2019-11-03actual | — | 2026-06-01 |
| A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and FemalesNCT03535571results2019-08-19The Change From Baseline (Day 0) to End-of-study (Day 128) in Energy Level After a 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)Open-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Dietary supplement: Salmon Protein Hydrolysate | Healthy | 20 | 2018-10-23actual | — | 2019-08-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19